INKT vs. TNYA, LPTX, XBIT, ATOS, ANRO, IVA, NVCT, DBVT, INZY, and TARA
Should you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Tenaya Therapeutics (TNYA), Leap Therapeutics (LPTX), XBiotech (XBIT), Atossa Therapeutics (ATOS), Alto Neuroscience (ANRO), Inventiva (IVA), Nuvectis Pharma (NVCT), DBV Technologies (DBVT), Inozyme Pharma (INZY), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry.
MiNK Therapeutics vs.
MiNK Therapeutics (NASDAQ:INKT) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.
In the previous week, Tenaya Therapeutics had 6 more articles in the media than MiNK Therapeutics. MarketBeat recorded 6 mentions for Tenaya Therapeutics and 0 mentions for MiNK Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.67 beat MiNK Therapeutics' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.
Tenaya Therapeutics received 21 more outperform votes than MiNK Therapeutics when rated by MarketBeat users. Likewise, 81.82% of users gave Tenaya Therapeutics an outperform vote while only 75.00% of users gave MiNK Therapeutics an outperform vote.
MiNK Therapeutics' return on equity of 0.00% beat Tenaya Therapeutics' return on equity.
2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 20.6% of MiNK Therapeutics shares are owned by insiders. Comparatively, 32.8% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
MiNK Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.
MiNK Therapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.89, meaning that its share price is 189% more volatile than the S&P 500.
MiNK Therapeutics presently has a consensus price target of $6.50, indicating a potential upside of 638.64%. Tenaya Therapeutics has a consensus price target of $17.33, indicating a potential upside of 1,138.10%. Given Tenaya Therapeutics' higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than MiNK Therapeutics.
Summary
Tenaya Therapeutics beats MiNK Therapeutics on 11 of the 14 factors compared between the two stocks.
Get MiNK Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiNK Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:INKT) was last updated on 1/21/2025 by MarketBeat.com Staff
Free INKT Stock Alerts